The HPV testing and Pap test market size was valued at USD 1.67 billion in 2020 and is expected to surpass USD 7.25 billion, expanding at a CAGR of 16.4% during the forecast period, 2021–2028. The growth of the market is attributed to the rising number of cervical cancer screening events and development of several innovative screening devices.
HPV testing and Pap test are primarily used for the detection of cancerous cells in the body. HPV or human papillomavirus consists of a group of more than 150 related viruses and Pap tests are widely used to identify tumor formation and precancers in the cervix. Precancers are mainly caused by HPV and some of the HPV types develops cervical cancer without proper treatment.
Market Trends, Drivers, Restraints, and Opportunities
- Rising number of cervical cancer cases worldwide present key factor driving the market growth.
- Increasing governments’ initiatives and policies for public awareness programs especially for women are another major factors for the market expansion.
- High incidence of cervical cancer especially vaginal cancer and increasing demand for innovative screening techniques for the treatment are major factors which are expected to drive the market growth.
- Increasing technology advancement in diagnostic procedures and development of several screening techniques by major players in the market are likely to boost the market.
- The COVID-19 pandemic and its dire consequences have impacted to enormously reduce regular cancer screening tests. This acts as a key restraining factor for the market.
Market Segment Insights
HPV testing segment is expected to grow at a rapid pace
Based on test types, the global HPV testing and Pap test market is bifurcated into HPV testing and Pap test. The HPV testing segment is expected to grow at a rapid pace during the projected period due to rising commercialization of innovative tests related to HPV infection. However, the Pap test segment is anticipated to account for a key share of the market during the forecast period owing to increasing awareness programs by healthcare authorities and rising implementation of policies to adopt mandatory screening of cervical cancer.
Vaginal cancer screening segment is projected to expand at a considerable CAGR
On the basis of applications, the market is bifurcated into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment is projected to hold a key market share in the coming years owing to higher incidence of cervical cancer and growing public-private initiatives to increase screening of cervical cancer. On the other hand, the vaginal cancer screening segment is anticipated to expand at a considerable CAGR during the forecast period due to high mortality rates of vaginal cancer and demand for screening test.
Consumables segment is expected to expand at a robust growth rate
Based on products, the global HPV testing and Pap test market is divided into instruments, consumables, and services. The services segment is anticipated to constitute a large market share during the projected period due to the increase in number of at-home screening of cervical cancer. On the other hand, the consumables segment is anticipated to expand at a robust growth rate during the forecast period owing to growing activities by key market players through the launch of novel consumables such as assays and kits for more precise HPV and Pap tests.
North America is anticipated to constitute a key market share
In terms of regions, the global HPV testing and Pap test market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key share of the market during the targeted period owing to increased awareness about early diagnosis of cervical cancer and healthcare remuneration scenarios in the region. On the other hand, the market of Asia Pacific is anticipated to expand at a healthy growth rate during the forecast period due to rising number of cancers and increasing adoption of advanced technology in the region.
Key players competing in the HPV testing and Pap test market are Abbott Laboratories; Qiagen N.V.; Becton, Dickinson and Company; Quest Diagnostics, Inc.; Hologic, Inc.; F. Hoffmann-La Roche AG; Femasys, Inc.; Arbor Vita Corporation; NURX, Inc.; Seegene, Inc.; Thermo Fisher Scientific, Inc.; and bioMérieux SA. Qiagen N.V. developed the QIAscreen HPV PCR Test, in November 2018, which was a molecular diagnostic test used to diagnose HPV.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]